Table 1.

Current clinical trials on immunotherapies for neurodegenerative diseases

	Drug	Trial phase	Epitope	Sponsor	Reference(s)
Aβ
Active immunotherapy: vaccines
ACI-24		I/II	1–15 aa	AC Immune SA	[72, 73]
Lu AF20513		I	1–12 aa, modified	H. Lundbeck A/S	[74]
Passive immunotherapy: antibodies
BAN2401		II	Protofibrils	Eisai Inc.	[75]
Crenezumab		II	12–23 aa	Genentech	[76]
Flebogamma		III	Immnunoglobulin	Instituto Grifols, S.A.	[77]
Gantenerumab		III	Conformational	Hoffman-La Roche	[78–80]
Solanezumab		III	13–28 aa	Eli Lilly	[81, 82]
α-Syn
Active immunotherapy: vaccines
AFFITOPE PD01A		I	NP	Affiris	[66, 83]
AFFITOPE PD03A		I	NP	Affiris	[66, 83]
Passive immunotherapy: antibodies
BIIB054		I	NP	Biogen
PRX002		I	C-terminus	Prothena Biosciences	[84]
Tau
Active immunotherapy: vaccines
AADvac-1		I	294–305 aa	Axon Neuroscience SE	[85]
ACI-35		I	Fragments (pS396, pS404)	AC Immune SA	[86]
Passive immunotherapy: antibodies
BMS-986168		I	eTau	Bristol-Myers Squibb	[87]
C2N-8E12		I	NP	C2N Diagnostics
RG7345		I	pS422	Hoffmann-La Roche	[88]

Information regarding clinical trials was found at clinicaltrials.gov and alzforum.org as of October 2015

Aβ = amyloid-β; α-Syn = α-synuclein; NP = not provided; aa = amino acids